Background and Objectives: An increased incidence of renal cell carcinoma (RCC)in obese patients has been reported by several authors.We investigated the associationof body mass index (BMI) with prognosis of patients with RCC.Methods: From January 1994 to December 2000, 693 operations for RCC in 683consecutive patients were performed at our institution. Patients’ BMI at operation wasevaluated, overall, tumor-specific and progression-free survival was investigated usingthe Kaplan–Meier method, for multivariate analysis the Cox regression model wasused.Results: Four hundred seventeen patients were males, 266 females. Mean age was62 years (range 16–88). BMI was available in 609 (89.2%). 371/609 (60.9%) ofpatients exhibited a BMI greater than 25. After a mean follow-up of 41.5 months, 86(12.6%) patients died from metastatic RCC, and 29 (4.3%) were alive with metastaticdisease. A significant advantage regarding overall (P¼0.015) and progression-free(0.017) but not tumor-specific survival (P¼0.057) was found for patients with a BMIof more than 25 compared to normal-weight patients. In multivariate analysis, BMIshowed no significant association with tumor-specific survival.Conclusions: Patients with a BMI of more than 25 had a better outcome compared topatients with normal weight in univariate analysis but not multivariate analysis.
Does overweight impact on the prognosis of patients with renal cell carcinoma? A single center experience of 683 patients
Schips L;
2004-01-01
Abstract
Background and Objectives: An increased incidence of renal cell carcinoma (RCC)in obese patients has been reported by several authors.We investigated the associationof body mass index (BMI) with prognosis of patients with RCC.Methods: From January 1994 to December 2000, 693 operations for RCC in 683consecutive patients were performed at our institution. Patients’ BMI at operation wasevaluated, overall, tumor-specific and progression-free survival was investigated usingthe Kaplan–Meier method, for multivariate analysis the Cox regression model wasused.Results: Four hundred seventeen patients were males, 266 females. Mean age was62 years (range 16–88). BMI was available in 609 (89.2%). 371/609 (60.9%) ofpatients exhibited a BMI greater than 25. After a mean follow-up of 41.5 months, 86(12.6%) patients died from metastatic RCC, and 29 (4.3%) were alive with metastaticdisease. A significant advantage regarding overall (P¼0.015) and progression-free(0.017) but not tumor-specific survival (P¼0.057) was found for patients with a BMIof more than 25 compared to normal-weight patients. In multivariate analysis, BMIshowed no significant association with tumor-specific survival.Conclusions: Patients with a BMI of more than 25 had a better outcome compared topatients with normal weight in univariate analysis but not multivariate analysis.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
